BioCryst’s Acquisition of Astria Expected to Close in the First Quarter of 2026 Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned with Topline Results Anticipated in Early 2027; First Patient Now Enrolled in the ORBIT-EXPANSE Long-Term Extension Trial Final Phase 1b/2 ALPHA-STAR Results in 29 HAE Patients... Read More

Final ALPHA-STAR Phase 1b/2 Results from the Full-Enrollment Population (n=29) Remain Highly Consistent with Prior Results from the Target-Enrollment Population (n=16), Demonstrating Strong Efficacy, Favorable Safety, and Potential for Infrequent Dosing Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned with... Read More

BOSTON / Oct 31, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final results from the ALPHA-STAR Phase 1b/2 trial of navenibart in people living with hereditary... Read More

Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE portfolio Solidifies double digit growth trajectory for HAE portfolio over the next decade BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction Implied... Read More

BOSTON / Oct 09, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present two posters at the Canadian Society of Allergy and Clinical Immunology (CSACI) 80 th Anniversary... Read More

BOSTON, Mass. / Oct 08, 2025 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the Phase 3 ORBIT-EXPANSE long-term trial of navenibart in people living with hereditary... Read More

BOSTON / Oct 03, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present one poster and one oral presentation at the 2025 HAEi Regional Conference EMEA, taking place... Read More

BOSTON / Oct 02, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 173,000 shares of Astria’s common stock on October 1, 2025 under Astria’s 2022 Inducement Stock... Read More

Results Support Potential for STAR-0310 to be Best-in-Class OX40 Antagonist STAR-0310 Exhibits Longest-in-Class Half-Life of 68 Days and Cytokine Suppression Lasting At Least 20 Weeks After a Single 300 mg SC Injection, Supporting Potential Every-Six-Month Administration STAR-0310 Was Well-Tolerated, with no ADCC-Related... Read More

BOSTON / Sep 03, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 128,000 shares of Astria’s common stock on September 2, 2025 under Astria’s 2022 Inducement Stock... Read More

BOSTON / Sep 03, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial data from the Phase 1a trial of STAR-0310 at the European Academy of Dermatology &... Read More

BOSTON / Aug 27, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global... Read More

Kaken Pharmaceutical, Co., Ltd. Will Pay Astria Therapeutics Up to $32 Million in Upfront and Milestone Payments, Plus Royalties for Japanese Development and Commercialization Rights Related to Navenibart Updated Cash Runway Supports the Company’s Operating Plan into 2028 ALPHA-ORBIT, A Pivotal Phase 3 Trial Evaluating Every... Read More

Up to $32 Million in Upfront and Milestone Payments, Plus Royalties Kaken Expertise in Commercializing Innovative Therapies Supports Navenibart’s Potential to be First-Choice HAE Treatment in Japan Updated Cash Runway Supports the Company’s Operating Plan Into 2028 BOSTON / Aug 06, 2025 / Business Wire / Astria Therapeutics,... Read More

BOSTON / Aug 04, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 180,000 shares of Astria’s common stock on August 1, 2025 under Astria’s 2022 Inducement Stock... Read More

BOSTON, Mass. / Jul 07, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the 2025 US Hereditary Angioedema Association (HAEA) National Summit,... Read More

BOSTON / Jul 02, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 119,860 shares of Astria’s common stock on July 1, 2025 under Astria’s 2022 Inducement Stock... Read More

BOSTON / Jun 18, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in a panel discussion at the Oppenheimer Innovators in Immunology & Inflammation (I&I) Summit... Read More

Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction Well-Tolerated with a Favorable Safety Profile All Patients Remain on Navenibart Long-Term Data are Highly Consistent with Previous Results and Support the Potential Market-Leading Profile of Navenibart,... Read More

BOSTON / Jun 06, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress,... Read More

BOSTON / Jun 03, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 62,000 shares of Astria’s common stock on June 2, 2025 under Astria’s 2022 Inducement Stock... Read More

BOSTON / May 28, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies... Read More

BOSTON / May 23, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the 14 th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary on May 31,... Read More

BOSTON / May 22, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the Eastern Allergy Conference (EAC) in Palm Beach, Florida on May 30, 2025. Raffi Tachdjian,... Read More

ALPHA-ORBIT Pivotal Phase 3 Trial Evaluating Every 3- and Every 6-Month Administration of Navenibart (STAR-0215) in Hereditary Angioedema is Enrolling Patients Upcoming Navenibart and STAR-0310 Data: ALPHA-SOLAR Long-Term Extension Trial Results Expected Mid-2025 and Phase 1a STAR-0310 Healthy Subject Results Expected in Q3... Read More

BOSTON / May 02, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 33,650 shares of Astria’s common stock on May 1, 2025 under Astria’s 2022 Inducement Stock Incentive... Read More

BOSTON / May 01, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that results from a Phase 1a trial in healthy subjects supporting navenibart’s potential to provide long-acting, safe,... Read More

BOSTON / Apr 30, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Citizens Life... Read More

BOSTON / Apr 02, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 43,650 shares of Astria’s common stock on April 1, 2025 under Astria’s 2022 Inducement Stock... Read More

ALPHA-ORBIT Pivotal Phase 3 Trial Evaluating Every 3- and Every 6-Month Administration of Navenibart (STAR-0215) in Hereditary Angioedema is Underway Initial Efficacy and Safety Data from Navenibart ALPHA-SOLAR Long-Term Extension Trial Expected Mid-2025 Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal... Read More

BOSTON / Mar 04, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 87,450 shares of Astria’s common stock on March 3, 2025 under Astria’s 2022 Inducement Stock... Read More

Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period BOSTON / Feb 27, 2025 / Business Wire / Astria Therapeutics, Inc . (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today... Read More

BOSTON / Feb 25, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming TD Cowen 45 th... Read More

BOSTON / Feb 20, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three posters at the American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy... Read More

BOSTON / Feb 04, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 16,500 shares of Astria’s common stock on February 3, 2025 under Astria’s 2022 Inducement Stock... Read More

BOSTON / Feb 04, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming virtual... Read More

BOSTON / Feb 03, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present quality of life results from the Phase 1b/2 trial of navenibart (STAR-0215) in a poster displayed... Read More

Early Proof-of-Concept Results from the Phase 1a Trial Anticipated in Q3 2025 BOSTON / Jan 23, 2025 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced initiation of a Phase 1a clinical trial... Read More

Single Pivotal Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period Pioneering Patient-Centric Dosing Flexibility in HAE with Potential Market-Leading First-Choice Profile Phase 3 Initiation On-Track, Expected in Q1 2025 Strong Financial Position, Funded... Read More

BOSTON / Jan 03, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 58,650 shares of Astria’s common stock on January 2, 2025 under Astria’s 2022 Inducement Stock... Read More

Navenibart Demonstrated 6 Months of HAE Attack Prevention with 1 or 2 Doses 90-95% Mean Monthly Attack Rate Reduction Supporting Chronic Dosing 2 or 4 Times Per Year 67% Attack-Free Rate Over 6 Months in Cohorts 2 and 3 Favorable Safety and Well-Tolerated Profile Phase 3 Initiation on Track for Q1 2025 BOSTON / Dec 11, 2024 /... Read More

Phase 1a Trial of STAR-0310 in Healthy Volunteers Expected to Initiate in Q1 2025 Early Proof-of-Concept Results Expected in Q3 2025 BOSTON / Dec 10, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases,... Read More

BOSTON / Dec 03, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 32,500 shares of Astria’s common stock on December 2, 2024 under Astria’s 2022 Inducement Stock... Read More

Navenibart (STAR-0215), the Potential Market-Leading Therapy for the Treatment of Hereditary Angioedema, on Track for Expected Phase 3 Initiation in Q1 2025 Final 3- and 6-Month Results from the ALPHA-STAR Trial of Navenibart Expected in Q4 2024 STAR-0310 Investigational New Drug (IND) Application Submission On-Track for... Read More

BOSTON / Nov 13, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies... Read More

BOSTON / Nov 04, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 210,000 shares of Astria’s common stock on November 1, 2024 under Astria’s 2022 Inducement Stock... Read More

BOSTON / Oct 30, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present interim quality of life results from the ALPHA-STAR trial of navenibart (STAR-0215) at the... Read More

BOSTON / Oct 21, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at the American College of Allergy, Asthma, and Immunology (ACAAI)... Read More

BOSTON / Oct 16, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to navenibart for the... Read More

BOSTON / Oct 02, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 52,000 shares of Astria’s common stock on October 1, 2024 under Astria’s 2022 Inducement Stock... Read More

BOSTON / Sep 30, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that navenibart (STAR-0215) has been granted Orphan Drug Designation for the treatment of hereditary angioedema (HAE)... Read More

BOSTON / Sep 27, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at the Global Angioedema Forum (GAF) in Copenhagen, Denmark on... Read More

BOSTON / Sep 19, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and... Read More

BOSTON / Sep 04, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 180,000 shares of Astria’s common stock on September 3, 2024 under Astria’s 2022 Inducement Stock... Read More

BOSTON / Aug 30, 2024 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present two posters at the upcoming Bradykinin Symposium in Berlin, Germany on September 6, 2024. Chris... Read More

BOSTON / Aug 29, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in the Morgan Stanley 22 nd Annual Global Healthcare Conference on September 5 th in New... Read More

Navenibart (STAR-0215), the Potential Market-Leading Therapy for the Treatment of Hereditary Angioedema, on Track for Expected Phase 3 Initiation in Q1 2025 Preclinical Results Support STAR-0310 as a Potential Best-in-Class OX40 Inhibitor BOSTON / Aug 12, 2024 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a... Read More

BOSTON / Aug 12, 2024 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has chosen Ypsomed as its partner for the development of an autoinjector for STAR-0215. “With STAR-0215's... Read More

BOSTON / Aug 07, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will participate in a panel focused on hereditary angioedema (HAE) at the 2024 Wedbush PacGrow Healthcare... Read More

BOSTON / Aug 02, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 29,150 shares of Astria’s common stock on August 1, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity... Read More

BOSTON / Jul 02, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 123,500 shares of Astria’s common stock on July 1, 2024 under Astria’s 2022 Inducement Stock... Read More

BOSTON / Jun 04, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 40,000 shares of Astria’s common stock on June 3, 2024 under Astria’s 2022 Inducement Stock... Read More

BOSTON / May 30, 2024 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies... Read More

BOSTON / May 24, 2024 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern... Read More

BOSTON / May 23, 2024 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI)... Read More

ALPHA-STAR Phase 1b/2 Trial Initial Proof-of-Concept Results Support Potential for STAR-0215 to Become the Market Leader in HAE with Q3M and Q6M Administration Preclinical Results for STAR-0310, Potential Best-in-Class OX40 Program for the Treatment of Atopic Dermatitis, to be Shared at Upcoming Society for Investigative... Read More

BOSTON / May 08, 2024 / Business Wire / Astria Therapeutics, Inc . (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present information on the preclinical profile of STAR-0310 at the upcoming Society for Investigative... Read More

BOSTON / May 02, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria’s common stock on May 1, 2024 under Astria’s 2022 Inducement Stock... Read More

BOSTON / Apr 09, 2024 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of... Read More

BOSTON / Apr 03, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 9,000 shares of Astria’s common stock on April 1, 2024 under Astria’s 2022 Inducement Stock... Read More

STAR-0215 Dosed Once or Twice Over 6 Months Reduced Monthly Attack Rates by 90-96%, Supporting Chronic Dosing 2 or 4 Times Per Year 92-100% Decrease in Moderate or Severe Attacks and 91-95% Reduction in Attacks Requiring Rescue Medications with STAR-0215 Very Well-Tolerated with No Serious Adverse Events and No... Read More

BOSTON / Mar 05, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 40,000 shares of Astria’s common stock on March 1, 2024 under Astria’s 2022 Inducement Stock... Read More

ALPHA-STAR Trial of STAR-0215 Initial Proof-of-Concept Data in HAE Patients Expected Q1 2024 STAR-0310, Potential Best-in-Class OX40 Program for the Treatment of Atopic Dermatitis, on Track for Expected IND Submission by Year-End 2024 and Phase 1a Initiation in Q1 2025 BOSTON / Mar 04, 2024 / Business Wire / Astria... Read More

BOSTON / Feb 20, 2024 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data at the upcoming American Academy of Allergy,... Read More

BOSTON / Feb 06, 2024 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming virtual... Read More

BOSTON / Feb 05, 2024 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 21,000 shares of Astria’s common stock on February 1, 2024 under Astria’s 2022 Inducement Stock... Read More

BOSTON / Jan 30, 2024 / Business Wire / Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the pricing of an underwritten offering of... Read More

BOSTON / Dec 04, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 52,000 shares of Astria’s common stock on December 1, 2023 under Astria’s 2022 Inducement Stock... Read More

BOSTON / Nov 27, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share STAR-0215 Phase 1a results in an encore presentation at the annual World Allergy Congress on... Read More

BOSTON / Nov 21, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and information on STAR-0215... Read More

New Phase 1a Results Confirm Potential for STAR-0215 to Prevent HAE Attacks with Dosing 2 or 4 Times Per Year ALPHA-STAR Trial of STAR-0215 Initial Proof-of-Concept Data in Patients Now Expected Q1 2024 STAR-0310, Potential Best-in-Class OX40 Program for the Treatment of Atopic Dermatitis, Expected IND Submission by Year-End... Read More

BOSTON / Nov 10, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, is presenting new STAR-0215 data in a poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) in... Read More

BOSTON / Nov 09, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and information on STAR-0215... Read More

BOSTON / Nov 03, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma,... Read More

BOSTON / Nov 02, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 36,800 shares of Astria’s common stock on November 1, 2023 under Astria’s 2022 Inducement Stock... Read More

BOSTON / Oct 30, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, will report third quarter 2023 financial results before the Nasdaq Global Market open on Monday, November 13, 2023. Jill C. Milne,... Read More

BOSTON / Oct 11, 2023 / Business Wire / Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the pricing of an underwritten offering of (i)... Read More

Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET BOSTON / Oct 11, 2023 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company... Read More

BOSTON / Oct 03, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 61,000 shares of Astria’s... Read More

BOSTON / Sep 06, 2023 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will be participating in two... Read More

BOSTON / Aug 31, 2023 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that preclinical data supporting... Read More

BOSTON / Aug 25, 2023 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information... Read More

STAR-0215 Granted Fast Track Designation by the U.S. FDA New Results from Healthy Subjects Informing STAR-0215 Administration Plan Expected in Q4 2023 ALPHA-STAR on Track with Initial Proof-of-Concept Results in Patients Anticipated Mid-2024 BOSTON / Aug 07, 2023 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a... Read More

BOSTON / Aug 02, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 174,000 shares of Astria’s... Read More

On Track for Proof-of-Concept Results in HAE Patients in Mid-2024 Results To-Date Support STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks BOSTON / Jul 20, 2023 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the... Read More

BOSTON / Jul 17, 2023 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it has named John Ruesch as... Read More

BOSTON / Jul 14, 2023 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information... Read More

BOSTON / Jul 06, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 60,000 shares of Astria’s... Read More

BOSTON / Jun 06, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 20,000 shares of Astria’s... Read More

BOSTON / Jun 05, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information on... Read More

BOSTON / May 31, 2023 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will... Read More

Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 Mechanistic Modeling Data Supports STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks BOSTON / May 11, 2023 /... Read More

BOSTON / May 02, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 12,000 shares of Astria’s... Read More

BOSTON / Apr 28, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information on... Read More

BOSTON / Apr 19, 2023 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, announced today that it has promoted Andrea Matthews... Read More

BOSTON / Apr 04, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 39,300 shares of Astria’s... Read More

ALPHA-STAR Phase 1b/2 Trial in People with HAE Underway with Initial Proof-of-Concept Results Anticipated Mid-2024 Phase 1a Results Support STAR-0215’s Target Profile as a Long-Acting Plasma Kallikrein Inhibitor with Estimated Half-Life of up to 117 Days Ended 4Q 2022 with Cash, Cash Equivalents, and Short-term Investments of... Read More

BOSTON / Mar 08, 2023 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter/full year 2022 financial... Read More

BOSTON / Mar 06, 2023 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will... Read More

BOSTON / Mar 02, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 10,000 shares of Astria’s... Read More

BOSTON / Feb 24, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, presented new STAR-0215 data in two poster presentations at... Read More

BOSTON / Feb 21, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will share new STAR-0215 data in two... Read More

BOSTON / Feb 08, 2023 / Business Wire / Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced the initiation of the ALPHA-STAR Phase... Read More

BOSTON / Feb 02, 2023 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 1,800 shares of Astria’s common stock on February 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022... Read More

Shown Early Proof of Concept of STAR-0215’s Profile as a Long-Acting Plasma Kallikrein Inhibitor with Estimated Half-Life of Up to 110 Days Plans to Initiate ALPHA-STAR Phase 1b/2 Trial in Hereditary Angioedema Patients in Q1 2023 Results to be discussed in a Webcast Today at 8:30am ET BOSTON--( BUSINESS WIRE )-- Astria... Read More